145 related articles for article (PubMed ID: 26260527)
41. Coffin-Siris syndrome is a SWI/SNF complex disorder.
Tsurusaki Y; Okamoto N; Ohashi H; Mizuno S; Matsumoto N; Makita Y; Fukuda M; Isidor B; Perrier J; Aggarwal S; Dalal AB; Al-Kindy A; Liebelt J; Mowat D; Nakashima M; Saitsu H; Miyake N; Matsumoto N
Clin Genet; 2014 Jun; 85(6):548-54. PubMed ID: 23815551
[TBL] [Abstract][Full Text] [Related]
42. Induction of sensitivity to doxorubicin and etoposide by transfection of MCF-7 breast cancer cells with heregulin beta-2.
Harris LN; Yang L; Tang C; Yang D; Lupu R
Clin Cancer Res; 1998 Apr; 4(4):1005-12. PubMed ID: 9563896
[TBL] [Abstract][Full Text] [Related]
43. Sodium salicylate is a novel catalytic inhibitor of human DNA topoisomerase II alpha.
Bau JT; Kurz EU
Biochem Pharmacol; 2011 Feb; 81(3):345-54. PubMed ID: 20959117
[TBL] [Abstract][Full Text] [Related]
44. The SWI/SNF complex--chromatin and cancer.
Roberts CW; Orkin SH
Nat Rev Cancer; 2004 Feb; 4(2):133-42. PubMed ID: 14964309
[No Abstract] [Full Text] [Related]
45. RSC, an essential, abundant chromatin-remodeling complex.
Cairns BR; Lorch Y; Li Y; Zhang M; Lacomis L; Erdjument-Bromage H; Tempst P; Du J; Laurent B; Kornberg RD
Cell; 1996 Dec; 87(7):1249-60. PubMed ID: 8980231
[TBL] [Abstract][Full Text] [Related]
46. [Relevance between TOP2A, EGFR gene expression and efficacy of docetaxel plus epirubicin as neoadjuvant chemotherapy in triple negative breast cancer patients].
Liu L; Li XR; Hu YH; Zhang J
Zhonghua Yi Xue Za Zhi; 2016 Mar; 96(12):940-3. PubMed ID: 27045718
[TBL] [Abstract][Full Text] [Related]
47. Expression of SMARCB1 modulates steroid sensitivity in human lymphoblastoid cells: identification of a promoter SNP that alters PARP1 binding and SMARCB1 expression.
Pottier N; Cheok MH; Yang W; Assem M; Tracey L; Obenauer JC; Panetta JC; Relling MV; Evans WE
Hum Mol Genet; 2007 Oct; 16(19):2261-71. PubMed ID: 17616514
[TBL] [Abstract][Full Text] [Related]
48. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
49. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia.
Lee SI; Celik S; Logsdon BA; Lundberg SM; Martins TJ; Oehler VG; Estey EH; Miller CP; Chien S; Dai J; Saxena A; Blau CA; Becker PS
Nat Commun; 2018 Jan; 9(1):42. PubMed ID: 29298978
[TBL] [Abstract][Full Text] [Related]
50. SMARCB1-deficient Vulvar Neoplasms: A Clinicopathologic, Immunohistochemical, and Molecular Genetic Study of 14 Cases.
Folpe AL; Schoolmeester JK; McCluggage WG; Sullivan LM; Castagna K; Ahrens WA; Oliva E; Biegel JA; Nielsen GP
Am J Surg Pathol; 2015 Jun; 39(6):836-49. PubMed ID: 25651469
[TBL] [Abstract][Full Text] [Related]
51. Correlation of chemosensitivity to anticancer drugs and telomere length, telomerase activity and telomerase RNA expression in human ovarian cancer cells.
Kiyozuka Y; Yamamoto D; Yang J; Uemura Y; Senzaki H; Adachi S; Tsubura A
Anticancer Res; 2000; 20(1A):203-12. PubMed ID: 10769656
[TBL] [Abstract][Full Text] [Related]
52. Lack of topoisomerase copy number changes in patients with de novo and relapsed diffuse large B-cell lymphoma.
Pedersen MØ; Poulsen TS; Gang AO; Knudsen H; Lauritzen AF; Pedersen M; Nielsen SL; Brown P; Høgdall E; Nørgaard P
Exp Hematol; 2015 Jul; 43(7):534-6. PubMed ID: 25931012
[TBL] [Abstract][Full Text] [Related]
53. Proteasomal inhibition potentiates drugs targeting DNA topoisomerase II.
Lee KC; Bramley RL; Cowell IG; Jackson GH; Austin CA
Biochem Pharmacol; 2016 Mar; 103():29-39. PubMed ID: 26794000
[TBL] [Abstract][Full Text] [Related]
54. p53 status identifies triple-negative breast cancer patients who do not respond to adjuvant chemotherapy.
Coradini D; Biganzoli E; Ardoino I; Ambrogi F; Boracchi P; Demicheli R; Daidone MG; Moliterni A
Breast; 2015 Jun; 24(3):294-7. PubMed ID: 25698149
[TBL] [Abstract][Full Text] [Related]
55. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type.
Karnezis AN; Wang Y; Ramos P; Hendricks WP; Oliva E; D'Angelo E; Prat J; Nucci MR; Nielsen TO; Chow C; Leung S; Kommoss F; Kommoss S; Silva A; Ronnett BM; Rabban JT; Bowtell DD; Weissman BE; Trent JM; Gilks CB; Huntsman DG
J Pathol; 2016 Feb; 238(3):389-400. PubMed ID: 26356327
[TBL] [Abstract][Full Text] [Related]
56. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human and mouse breast cancer cells.
Asano T; Kleinerman ES; Zwelling LA; Zhou Z; Fukunaga Y
Acta Oncol; 2005; 44(3):240-7. PubMed ID: 16076696
[TBL] [Abstract][Full Text] [Related]
57. Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cells.
Wu Q; Sharma S; Cui H; LeBlanc SE; Zhang H; Muthuswami R; Nickerson JA; Imbalzano AN
Oncotarget; 2016 May; 7(19):27158-75. PubMed ID: 27029062
[TBL] [Abstract][Full Text] [Related]
58. Novel DNA topoisomerase IIα inhibitors from combined ligand- and structure-based virtual screening.
Drwal MN; Marinello J; Manzo SG; Wakelin LP; Capranico G; Griffith R
PLoS One; 2014; 9(12):e114904. PubMed ID: 25489853
[TBL] [Abstract][Full Text] [Related]
59. Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.
Martin M; Romero A; Cheang MC; López García-Asenjo JA; García-Saenz JA; Oliva B; Román JM; He X; Casado A; de la Torre J; Furio V; Puente J; Caldés T; Vidart JA; Lopez-Tarruella S; Diaz-Rubio E; Perou CM
Breast Cancer Res Treat; 2011 Jul; 128(1):127-36. PubMed ID: 21465170
[TBL] [Abstract][Full Text] [Related]
60. Autophagy-Dependent Sensitization of Triple-Negative Breast Cancer Models to Topoisomerase II Poisons by Inhibition of the Nucleosome Remodeling Factor.
Tyutyunyk-Massey L; Sun Y; Dao N; Ngo H; Dammalapati M; Vaidyanathan A; Singh M; Haqqani S; Haueis J; Finnegan R; Deng X; Kirberger SE; Bos PD; Bandyopadhyay D; Pomerantz WCK; Pommier Y; Gewirtz DA; Landry JW
Mol Cancer Res; 2021 Aug; 19(8):1338-1349. PubMed ID: 33811160
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
